Found: 8
Select item for more details and to access through your institution.
A prospective feasibility study of uracil–tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 4, p. 317, doi. 10.1007/s00280-023-04526-7
- By:
- Publication type:
- Article
Impact of pre-hydration duration on high-dose methotrexate induced nephrotoxicity in childhood acute lymphoblastic leukaemia in resource constraint centers: a randomized crossover study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 4, p. 331, doi. 10.1007/s00280-023-04525-8
- By:
- Publication type:
- Article
A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 4, p. 345, doi. 10.1007/s00280-023-04523-w
- By:
- Publication type:
- Article
Correction to: A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 4, p. 303, doi. 10.1007/s00280-023-04521-y
- By:
- Publication type:
- Article
Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 4, p. 337, doi. 10.1007/s00280-023-04519-6
- By:
- Publication type:
- Article
Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 4, p. 325, doi. 10.1007/s00280-023-04514-x
- By:
- Publication type:
- Article
A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 4, p. 291, doi. 10.1007/s00280-023-04507-w
- By:
- Publication type:
- Article